AIM IMMUNOTECH (Germany) Top Insiders
| HXB2 Stock | EUR 0.36 0.01 2.86% |
AIM IMMUNOTECH employs about 21 people. The company is managed by 7 executives with a total tenure of roughly 55 years, averaging almost 7.0 years of service per executive, having 3.0 employees per reported executive. Examination of AIM IMMUNOTECH's management performance can provide insight into the company performance.
| Thomas Equels Chairman Executive Vice Chairman, Chief Executive Officer, President, Secretary, & General Counsel |
AIM |
AIM IMMUNOTECH Management Team Effectiveness
The company has return on total asset (ROA) of (0.229) % which means that it has lost $0.229 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3991) %, meaning that it generated substantial loss on money invested by shareholders. AIM IMMUNOTECH's management efficiency ratios could be used to measure how well AIM IMMUNOTECH manages its routine affairs as well as how well it operates its assets and liabilities.AIM IMMUNOTECH Workforce Comparison
AIM IMMUNOTECH INC is rated # 3 in number of employees category among related companies. The total workforce of Biotechnology industry is currently estimated at about 58,414. AIM IMMUNOTECH adds roughly 21.0 in number of employees claiming only tiny portion of stocks in Biotechnology industry.
AIM IMMUNOTECH INC Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. AIM IMMUNOTECH INC Price Series Summation is a cross summation of AIM IMMUNOTECH price series and its benchmark/peer.
AIM IMMUNOTECH Notable Stakeholders
An AIM IMMUNOTECH stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as AIM IMMUNOTECH often face trade-offs trying to please all of them. AIM IMMUNOTECH's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting AIM IMMUNOTECH's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Thomas Equels | Executive Vice Chairman, Chief Executive Officer, President, Secretary, & General Counsel | Profile | |
| Ellen Lintal | Chief Financial Officer | Profile | |
| Peter Rodino | Chief Operating Officer, General Counsel, Secretary | Profile | |
| Wayne Springate | Senior Vice President - Operations | Profile | |
| Stewart Appelrouth | Director | Profile | |
| David Strayer | Chief Scientific & Medical Officer | Profile | |
| William Mitchell | Chairman of the Board | Profile |
About AIM IMMUNOTECH Management Performance
The success or failure of an entity such as AIM IMMUNOTECH INC often depends on how effective the management is. AIM IMMUNOTECH management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of AIM management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the AIM management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viruses, and immune-deficiency disorders in the United States. AIM ImmunoTech Inc. was incorporated in 1990 and is headquartered in Ocala, Florida. AIM IMMUNOTECH operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 21 people.
The data published in AIM IMMUNOTECH's official financial statements usually reflect AIM IMMUNOTECH's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of AIM IMMUNOTECH INC. For example, before you start analyzing numbers published by AIM accountants, it's critical to develop an understanding of what AIM IMMUNOTECH's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of AIM IMMUNOTECH's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, AIM IMMUNOTECH's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in AIM IMMUNOTECH's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of AIM IMMUNOTECH INC. Please utilize our Beneish M Score to check the likelihood of AIM IMMUNOTECH's management manipulating its earnings.
AIM IMMUNOTECH Workforce Analysis
Traditionally, organizations such as AIM IMMUNOTECH use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare AIM IMMUNOTECH within its industry.AIM IMMUNOTECH Manpower Efficiency
Return on AIM IMMUNOTECH Manpower
| Revenue Per Employee | 6.4K | |
| Revenue Per Executive | 19.3K | |
| Net Loss Per Employee | 795.2K | |
| Net Loss Per Executive | 2.4M |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in AIM IMMUNOTECH INC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For more detail on how to invest in AIM Stock please use our How to Invest in AIM IMMUNOTECH guide.Note that the AIM IMMUNOTECH INC information on this page should be used as a complementary analysis to other AIM IMMUNOTECH's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Complementary Tools for AIM Stock analysis
When running AIM IMMUNOTECH's price analysis, check to measure AIM IMMUNOTECH's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AIM IMMUNOTECH is operating at the current time. Most of AIM IMMUNOTECH's value examination focuses on studying past and present price action to predict the probability of AIM IMMUNOTECH's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AIM IMMUNOTECH's price. Additionally, you may evaluate how the addition of AIM IMMUNOTECH to your portfolios can decrease your overall portfolio volatility.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |